Retargeted Psychopharm

Aus coViki
Wechseln zu: Navigation, Suche


  • GET 2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis. Extract

Valproic acid

  • GET 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Extract


  • GET ä. Repositionnement de la chlorpromazine ... Extract psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments
  • paper
  • GET 2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19. Extract
  • GET 2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Extract


  • GET 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate. Extract


  • GET 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) Extract


  • GET ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Extract
  • GET 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic Extract
  • GET 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter. Extract
  • GET 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
  • GET 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? Extract . Extract
  • GET 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? Extract
  • GET 2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. Extract


  • GET ä. Oxytocin as a potential defence against Covid-19? Extract
Meine Werkzeuge